Background: Social comparisons (SCs) are common among cancer patients, but
may use other women as sources of information to judge her own status, a behavior termed social comparison (SC). 3 SC can reduce uncertainty or anxiety associated with the threatening experience of having a cancer diagnosis if one's own status is similar to others. 4, 5 Studies show that women with breast cancer regularly encounter potential sources of SC (eg, in doctors' office waiting rooms and media coverage), 6, 7 and cancer patients are interested in SCs as a source of information. 8 SCs are characterized by their direction (upward vs downward) and interpretation (identification vs contrast), which converge to describe four SCs. 9, 10 Upward identification focuses on how one is similar to better-off others and may provide information about how to improve one's situation. 11, 12 Upward contrast focuses on how one is different from better-off others, which may be threatening. 13, 14 Downward identification focuses on how one is similar to worse-off others and makes salient the possibility of one's own condition deteriorating. 13, 15 Downward contrast focuses on how one is different from worse-off others and suggests that the differences are large or stable. 7, 13, 15 SC is not unique to cancer and has been widely studied across other contexts (eg, cardiovascular disease, 5 depression, 13 and occupational burnout 16 ).
A recent meta-analysis incorporating 60+ years of research concluded that upward and contrasting SCs were most common. 17 Psychosocial well-being is an aspect of the cancer experience for which there are few objective indicators of one's status. Nonetheless,
health-related quality of life (HRQOL) and depressive symptoms are two well-studied aspects of the cancer experience. Prior work in cancer shows that perceiving oneself as better-off than patients with worse cancer (downward contrast) can buffer against diminished HRQOL in the context of worsening physical well-being. 18 Further, SCs related to coping and emotional reactions to cancer can affect HRQOL up to 3 months postexposure. [19] [20] [21] Less work in cancer has focused on relationships between SCs and depressive symptoms. In one study, elevated depressive symptoms were associated with a greater perceived need for SC information. 8 A separate study of college students found that downward SCs were helpful for individuals experiencing elevated depressive symptoms 13 ; however, whether this extends to persons with cancer is not currently known.
There are multiple challenges to interpreting past findings of SCs in cancer patients. First, the majority of research has been crosssectional, and long-term associations of SCs with psychosocial wellbeing (eg, HRQOL and depressive symptoms) are not well understood beyond 3 months. Second, much of the existing research focuses on cancer survivors who have completed treatment 10, 20, 21 or has included patients at various timepoints throughout the cancer trajectory. 6, 7, [22] [23] [24] More information is needed regarding SCs early in cancer treatment, when contextual threat may be high. Third, research suggests that factors including type of cancer and treatment regimen may influence reactions to SCs. 5 Thus, studies that include diverse cancer diagnoses and stages (ie, early stage vs advanced) may not generalize to specific disease groups. Finally, personality differences can predispose individuals to more positive or negative outcomes as a result of SCs. 5 For example, greater dispositional optimism is linked to less negative affect after SC. 13, 25 Thus, personality characteristics such as optimism should be considered when assessing SCs.
This study sought to address these limitations by examining SCs among women newly diagnosed with nonmetastatic breast cancer across the first year of cancer treatment while controlling for stage of disease, dispositional optimism, and intervention condition (see below)
within the framework of SC theory. We aimed to assess the crosssectional associations of SCs with HRQOL and depressive symptoms at two timepoints (postdiagnosis/surgery but before beginning adjuvant therapies, and 6 months later). We hypothesized that upward identification and downward contrast SCs would be associated with better HRQOL and less depressive symptoms at both timepoints, whereas upward contrast and downward identification SCs would be associated with poorer HRQOL and more depressive symptoms. We also aimed to assess the prospective associations of SCs with HRQOL and depressive symptoms from baseline to 6 months, from baseline to 12 months, and from 6 to 12 months. We hypothesized the same directions of associations of SCs with HRQOL and depressive symptoms as in the first aim. We approached 502 women for this study, of whom 106 did not meet inclusion criteria and 156 declined to participate. In total, 240 women provided written informed consent, enrolled, and completed a baseline assessment (T1). Participants self-reported demographic and socioeconomic information at enrollment. The baseline assessment included self-reported measures of SCs, optimism, and HRQOL, and a structured interview to assess depressive symptoms. Participants were reassessed 6 (T2) and 12 months (T3) later.
Participants were randomized to CBSM or a 1-day psychoeducational control group. Women in CBSM participated in a 10-week group-based intervention including elements of cognitivebehavioral therapy and relaxation training (see reports by Antoni et al 26, 27 ). The control condition received a condensed educational version of the intervention material as part of a 1-day psychoeducational seminar but did not benefit from group support or practice of intervention techniques. CBSM was not designed to affect SCs, and SCs were not discussed in the intervention or control conditions.
| Measures

| Social comparisons
We used a self-constructed scale to assess SC frequencies, each with one item: How often do you think about … "yourself as being worse off than women who don't have breast cancer?" (upward contrast), "getting to be as well off as women who've completely recovered from their breast cancer?" (upward identification), "women whose breast cancer is worse than yours and think about the possibility of being in their situation?" (downward identification), "women whose breast cancer is worse than yours and think about how much better off you are than they are?" (downward contrast). Responses ranged from 0 = not at all to 4 = almost constantly.
| Health-related quality of life
The 27 
| Depressive symptoms
The 17-item interview-based Hamilton Rating Scale for Depression (HRSD) assessed for the presence and severity of depressive symptoms over the past week. 29 A clinical psychologist with extensive training in using the HRSD trained study assessors using the structured interview guide. 30 Possible scores range from 0 to 23 with higher scores reflecting greater symptomatology. Chronbach's alphas were acceptable (range 0.78-0.80).
| Dispositional optimism
On the six-item (plus three filler items) Life Orientation TestRevised, 31 participants indicated their agreement with statements such as "in uncertain times, I usually expect the best" on a Likert scale from 1 = I agree a lot to 4 = I disagree. After appropriate reverse scoring, items were summed so higher scores represent greater optimism.
Cronbach's alpha was acceptable (0.77).
| Statistical analysis
Power calculations were based on our prior study in breast cancer. We projected that with 210 participants retained at T3 and a 0.05 alpha level, we would have a power of 0.95 to detect medium intervention effects on the primary outcomes. We screened all variables for outliers (greater than three standard deviations from the mean) and inspected distributions for skewness, kurtosis, and multivariate assumptions of normality. 32 We used means, standard deviations, frequencies, and general linear modeling to characterize the sample and assess changes in study variables over time.
We conducted path analysis using structural equation modeling in Mplus Version 7. 33 The main model ( and HRQOL and depressive symptoms were specified to correlate at T2 and T3. Although CBSM was not designed to affect SCs, it is possible that cognitive-behavioral techniques (eg, cognitive reframing)
could affect the types of SCs women make over time. Thus, after establishing the main models, study condition (CBSM vs control) was added as a covariate.
Missing data were estimated using full information maximum likelihood, which yields population estimates using all observed data to ensure that each participant is represented in the analyses. We 
| Sample characteristics
See Table 2 for all standardized coefficients.
| Cross-sectional associations
T1 upward contrast and downward identification were negatively associated with concurrent HRQOL. That is, in the time after breast cancer diagnosis/surgery and before beginning other adjuvant therapies (baseline), more frequently thinking that you are worse off than women who do not have breast cancer (upward contrast) and that you are similar to women with worse breast cancer (downward identification) were associated with poorer HRQOL.
| Prospective associations
T1 upward contrast predicted better T2 HRQOL and less T2 depressive symptoms (marginal association), and T1 upward identification predicted more T2 depressive symptoms. In other words, at baseline, more frequently thinking that you are worse off than women who do not have breast cancer (upward contrast) predicted better HRQOL and less depressive symptoms (marginally) 6 months later. More frequently thinking that you are similar to women who have recovered from breast cancer (upward identification) predicted more depressive symptoms 6 months later.
| Intervention effects
All significant associations held after controlling for study condition.
Condition was not associated with T1 SCs, stage, or optimism, or with T2 HRQOL or depressive symptoms (Ps > 0.05).
| Model 2: T1-T3
Model 2 ( Figure 2B ) fit the data well (χ Table 2 for all standardized coefficients.
| Cross-sectional associations
Cross-sectional associations between T1 SCs, HRQOL, and depressive symptoms in this model were identical to those reported in model 1.
| Prospective associations
Consistent with model 1, T1 upward contrast predicted better T3 HRQOL.
| Intervention effects
CBSM was associated with better T3 HRQOL (β = 0.11, P = 0.028) and fewer T3 depressive symptoms (β = −0.14, P = 0.027). Abbreviations: M, mean; n, frequency; SD, standard deviation; T1 n = 240; T1, baseline; T2 n = 194; T2, 6 months; T3 n = 192; T3, 12 months.
| Model 3: T2-T3
Model 3 ( Figure 2C ) fit the data acceptably (χ 2 4 = 9.91, P = 0.042; CFI = 0.98; RMSEA = 0.08; SRMR = 0.02). See Table 2 for all standardized coefficients. 
| Prospective associations
T2 downward identification predicted poorer T3 HRQOL and more T3 depressive symptoms (marginal association). In other words, approximately 6 months after initiating adjuvant therapies, more frequently thinking that you are similar to women with worse breast cancer (downward identification) predicted poorer HRQOL and more depressive symptoms (marginally) 6 months later (12 months postdiagnosis/surgery).
| Intervention effects
CBSM was marginally associated with upward contrast at T2 (β = 0.12, P = 0.080). All other associations with study condition were nonsignificant (Ps > 0.050). This study examined the associations of SCs with HRQOL and depressive symptoms among women with newly diagnosed nonmetastatic breast cancer at three timepoints-postdiagnosis/surgery and before beginning adjuvant therapies (T1), and 6 (T2) and 12 months later (T3). Consistent with our hypotheses, upward contrast was associated with poorer concurrent HRQOL at T1 and T2 (medium and small effects, respectively) and with more concurrent depressive symptoms at T2 (small effect) but not at T1. Contrary to our hypotheses, T1
upward contrast subsequently predicted better HRQOL at T2 and T3 (small effects) and less depressive symptoms at T3 (marginal association). Further, T1 upward identification predicted more T2 depressive symptoms (small effect), and T2 upward identification was associated with poorer concurrent HRQOL and depressive symptoms (small effects). As expected, T1 downward identification was associated with poorer concurrent HRQOL (small effect), and T2 downward identification predicted poorer T3 HRQOL (small effect) and more T3
depressive symptoms (marginal association).
Results suggest that in the time after diagnosis/surgery, recognizing the differences between oneself and women without breast cancer (upward contrast) and identifying with other breast cancer patients (downward identification), essentially facing the reality of a breast cancer diagnosis, are detrimental to immediate HRQOL. Indeed, almost one third of newly diagnosed breast cancer patients experience clinically elevated distress. 35 However, we found that facing this new reality was protective for HRQOL up to 12 months later. This is consistent with studies showing that coping through denial post breast cancer diagnosis is detrimental over time, whereas postdiagnosis acceptance predicts more positive adjustment. 36, 37 It is possible that our observed pattern of SCs reflect how denial may be initially protective and
acceptance threatening yet have the opposite effects over time.
Our findings suggest that upward comparisons (both contrast and identification) approximately 6 months postdiagnosis/surgery were associated with poorer concurrent psychosocial well-being. This is consistent with work suggesting that upward comparisons are threatening, inasmuch as they place the self in an unfavorable position. 13, 14 There may be something unique about this particular timepoint, at which many women were completing primary treatment, which makes upward comparisons particularly threatening.
This study has important strengths. The sample was homogeneous, as all participants were women with newly diagnosed nonmetastatic breast cancer. Focusing exclusively on breast cancer patients and recruiting them at a distinct time eliminated many between-subject differences that may influence the associations of interest. 5 We included theoretically relevant covariates, ensuring that the observed associations were significant above the effects of potential confounders. Finally, we used a longitudinal design and robust statistical methodology, allowing for relationships to emerge over a longer period of time than has been previously reported. [19] [20] [21] Notably, these studies have been conducted with cancer patients at various points in the cancer trajectory.
Our findings suggest that the associations of SCs with psychosocial well-being persist across the first year of breast cancer treatment. Perhaps this timeframe, during which contextual threat is high, lends itself to SC intervention. Future research should investigate this possibility.
| CONCLUSIONS
This study provides evidence that SCs during the first 6 months after breast cancer diagnosis can affect concurrent HRQOL and depressive symptoms as well as prospective outcomes up to 6 and 12 months later. Upward SCs were related to compromised concurrent psychosocial well-being, but prospective effects varied by the interpretation of the comparison (ie, contrast vs identification). Findings have implications for the development and deployment of group-based psychosocial interventions during the early phases of survivorship, during which opportunities for SC are prevalent.
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